ARTICLE | Clinical News
Agrylin anagrelide inhibitor of cyclic AMP phosphodiesterase regulatory update
January 8, 2001 8:00 AM UTC
Europe granted Orphan Drug designation for Agrylin to treat essential thrombocythemia. The product is marketed in the U.S., where it has Orphan Drug status. ...